社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
miaomee
IP属地：未知
+关注
帖子 · 267
帖子 · 267
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
miaomee
miaomee
·
2021-12-28
Comment n like
Novavax Shares Jumped 3% in Morning Trading
Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.
Novavax Shares Jumped 3% in Morning Trading
看
2,107
回复
2
点赞
8
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-24
Like n comment pls
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
看
1,931
回复
2
点赞
4
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-23
Like n comment
非常抱歉，此主贴已删除
看
2,068
回复
1
点赞
3
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-21
Comment
非常抱歉，此主贴已删除
看
2,556
回复
1
点赞
4
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-21
Nice
Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.
Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%. Pfizer
Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.
看
2,527
回复
2
点赞
3
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-20
Like n comment pls
非常抱歉，此主贴已删除
看
2,269
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-08
Comment n like pls
New Street Research raised Tesla's target price to $1580, the highest price on Wall Street
Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesl
New Street Research raised Tesla's target price to $1580, the highest price on Wall Street
看
2,473
回复
2
点赞
6
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-08
Wow
New Street Research raised Tesla's target price to $1580, the highest price on Wall Street
Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesl
New Street Research raised Tesla's target price to $1580, the highest price on Wall Street
看
2,133
回复
评论
点赞
3
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-06
Like n comment pls
Apple stock surged more than 3% in morning trading
Apple stock surged more than 3% in morning trading.Apple plans to produce up to 96 million iPhones f
Apple stock surged more than 3% in morning trading
看
2,366
回复
2
点赞
6
编组 21备份 2
分享
举报
miaomee
miaomee
·
2021-12-06
Comment n like pls
非常抱歉，此主贴已删除
看
2,492
回复
4
点赞
8
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3569375896365334","uuid":"3569375896365334","gmtCreate":1606294459318,"gmtModify":1621085770636,"name":"miaomee","pinyin":"miaomee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":36,"headSize":413,"tweetSize":267,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696223088,"gmtCreate":1640706454734,"gmtModify":1640706455124,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Comment n like ","listText":"Comment n like ","text":"Comment n like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696223088","repostId":"1150918555","repostType":4,"repost":{"id":"1150918555","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640702663,"share":"https://www.laohu8.com/m/news/1150918555?lang=&edition=full","pubTime":"2021-12-28 22:44","market":"us","language":"en","title":"Novavax Shares Jumped 3% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1150918555","media":"Tiger Newspress","summary":"Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.","content":"<p>Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/d7f50d71385e7262972c51f222a641a6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Shares Jumped 3% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Shares Jumped 3% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/d7f50d71385e7262972c51f222a641a6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150918555","content_text":"Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698339602,"gmtCreate":1640302478946,"gmtModify":1640302480586,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698339602","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b> announced Wednesday its oral COVID-19 antiviral pill, <b>Paxlovid,</b> has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of <b>Merck & Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b> Pfizer shares closed lower 1.41% to $58.71 on Thursday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-24 07:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pfizer, Inc.</b> announced Wednesday its oral COVID-19 antiviral pill, <b>Paxlovid,</b> has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of <b>Merck & Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b> Pfizer shares closed lower 1.41% to $58.71 on Thursday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691716023,"gmtCreate":1640242845790,"gmtModify":1640242846200,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Like n comment ","listText":"Like n comment ","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691716023","repostId":"2193118401","repostType":4,"isVote":1,"tweetType":1,"viewCount":2068,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691053623,"gmtCreate":1640100826869,"gmtModify":1640100827266,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Comment ","listText":"Comment ","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691053623","repostId":"1131687838","repostType":4,"isVote":1,"tweetType":1,"viewCount":2556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691022473,"gmtCreate":1640100368531,"gmtModify":1640100368982,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691022473","repostId":"1148529089","repostType":4,"repost":{"id":"1148529089","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640098401,"share":"https://www.laohu8.com/m/news/1148529089?lang=&edition=full","pubTime":"2021-12-21 22:53","market":"us","language":"en","title":"Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148529089","media":"Tiger Newspress","summary":"Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.\nPfizer","content":"<p>Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.</p>\n<p>Pfizer fell more than 5%, Novavax fell nearly 10%.<img src=\"https://static.tigerbbs.com/8965c7ba2ab9d4149e37dd1a91113e13\" tg-width=\"717\" tg-height=\"600\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-21 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.</p>\n<p>Pfizer fell more than 5%, Novavax fell nearly 10%.<img src=\"https://static.tigerbbs.com/8965c7ba2ab9d4149e37dd1a91113e13\" tg-width=\"717\" tg-height=\"600\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148529089","content_text":"Vaccine stocks fell sharply in morning trading, with Vir Biotechnology falling more than 10%.\nPfizer fell more than 5%, Novavax fell nearly 10%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2527,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693659087,"gmtCreate":1640015694712,"gmtModify":1640015695097,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693659087","repostId":"2192901606","repostType":2,"isVote":1,"tweetType":1,"viewCount":2269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602345926,"gmtCreate":1638976350670,"gmtModify":1638976381530,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Comment n like pls","listText":"Comment n like pls","text":"Comment n like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602345926","repostId":"1151922226","repostType":2,"repost":{"id":"1151922226","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638970132,"share":"https://www.laohu8.com/m/news/1151922226?lang=&edition=full","pubTime":"2021-12-08 21:28","market":"us","language":"en","title":"New Street Research raised Tesla's target price to $1580, the highest price on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1151922226","media":"Tiger Newspress","summary":"Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesl","content":"<p>Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.</p>\n<p><img src=\"https://static.tigerbbs.com/1f80f033625e9027d5042d14fb5202da\" tg-width=\"851\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>New Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.</p>\n<p>Analyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.</p>\n<p>Expect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.</p>\n<p>New Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Street Research raised Tesla's target price to $1580, the highest price on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Street Research raised Tesla's target price to $1580, the highest price on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.</p>\n<p><img src=\"https://static.tigerbbs.com/1f80f033625e9027d5042d14fb5202da\" tg-width=\"851\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>New Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.</p>\n<p>Analyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.</p>\n<p>Expect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.</p>\n<p>New Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151922226","content_text":"Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.\n\nNew Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.\nAnalyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.\nExpect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.\nNew Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602342522,"gmtCreate":1638976330496,"gmtModify":1638976330817,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602342522","repostId":"1151922226","repostType":2,"repost":{"id":"1151922226","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638970132,"share":"https://www.laohu8.com/m/news/1151922226?lang=&edition=full","pubTime":"2021-12-08 21:28","market":"us","language":"en","title":"New Street Research raised Tesla's target price to $1580, the highest price on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1151922226","media":"Tiger Newspress","summary":"Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesl","content":"<p>Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.</p>\n<p><img src=\"https://static.tigerbbs.com/1f80f033625e9027d5042d14fb5202da\" tg-width=\"851\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>New Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.</p>\n<p>Analyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.</p>\n<p>Expect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.</p>\n<p>New Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Street Research raised Tesla's target price to $1580, the highest price on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Street Research raised Tesla's target price to $1580, the highest price on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.</p>\n<p><img src=\"https://static.tigerbbs.com/1f80f033625e9027d5042d14fb5202da\" tg-width=\"851\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p>\n<p>New Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.</p>\n<p>Analyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.</p>\n<p>Expect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.</p>\n<p>New Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151922226","content_text":"Tesla shares changed from decline to rise in premarket trading after New Street Research raised Tesla's target price to $1580, the highest price on Wall Street.\n\nNew Street Research boosts its price target on Tesla to $1,580 to mark a new Street high.\nAnalyst Pierre Ferragu and team point to multiple strong catalysts for Tesla in looking ahead to 2022. Tesla is seen ending this year with an annualized production run-rate of well above 1M units and being likely to deliver a strong Q4 earnings beat. Production out of Berlin and Texas is anticipated to ramp during the year to help the automaker hit 1.5M total deliveries vs. 1.4M consensus and margins are seen cracking the 30% level by the end of the year, despite the ramp of the two factories. Further manufacturing efficiency improvements could help in that regard.\nExpect to hear more 4680 talk with Tesla in the year ahead. \"We expect 4680 production to be in full swing by year end and grow rapidly from there, and new sites to break ground in order to maintain ~50% annual growth,\" previews Ferragu.\nNew Street Research's price target of $1,580 is based on TSLA trading comfortably at the higher end of the 50X to 100X P/E range. The PT reps right at 50% upside for Tesla from yesterday's closing price and is well in front of the all-time high of $1,243.49.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606901497,"gmtCreate":1638804470921,"gmtModify":1638804471245,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606901497","repostId":"1117755408","repostType":2,"repost":{"id":"1117755408","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638801900,"share":"https://www.laohu8.com/m/news/1117755408?lang=&edition=full","pubTime":"2021-12-06 22:45","market":"us","language":"en","title":"Apple stock surged more than 3% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1117755408","media":"Tiger Newspress","summary":"Apple stock surged more than 3% in morning trading.Apple plans to produce up to 96 million iPhones f","content":"<p>Apple stock surged more than 3% in morning trading.Apple plans to produce up to 96 million iPhones for the first half of 2021, a nearly 30% year-on-year increase, after demand for its first-ever 5G handsets surged amid the pandemic, according to Nikkei Asia.</p>\n<p>The Cupertino-based tech giant has asked suppliers to build some 95 million to 96 million iPhones, including the latest iPhone 12 range and the older iPhone 11 and iPhone SE, multiple people familiar with the matter said -- though industrywide shortages of key components could threaten that target.</p>\n<p><img src=\"https://static.tigerbbs.com/55a8103513629aeb04b5256e70aa8380\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple stock surged more than 3% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple stock surged more than 3% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-06 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple stock surged more than 3% in morning trading.Apple plans to produce up to 96 million iPhones for the first half of 2021, a nearly 30% year-on-year increase, after demand for its first-ever 5G handsets surged amid the pandemic, according to Nikkei Asia.</p>\n<p>The Cupertino-based tech giant has asked suppliers to build some 95 million to 96 million iPhones, including the latest iPhone 12 range and the older iPhone 11 and iPhone SE, multiple people familiar with the matter said -- though industrywide shortages of key components could threaten that target.</p>\n<p><img src=\"https://static.tigerbbs.com/55a8103513629aeb04b5256e70aa8380\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117755408","content_text":"Apple stock surged more than 3% in morning trading.Apple plans to produce up to 96 million iPhones for the first half of 2021, a nearly 30% year-on-year increase, after demand for its first-ever 5G handsets surged amid the pandemic, according to Nikkei Asia.\nThe Cupertino-based tech giant has asked suppliers to build some 95 million to 96 million iPhones, including the latest iPhone 12 range and the older iPhone 11 and iPhone SE, multiple people familiar with the matter said -- though industrywide shortages of key components could threaten that target.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606909386,"gmtCreate":1638804324058,"gmtModify":1638804324408,"author":{"id":"3569375896365334","authorId":"3569375896365334","name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3569375896365334","idStr":"3569375896365334"},"themes":[],"htmlText":"Comment n like pls","listText":"Comment n like pls","text":"Comment n like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/606909386","repostId":"1167580246","repostType":2,"isVote":1,"tweetType":1,"viewCount":2492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}